Yuhan Corporation Central Research Institute. Courtesy of Yuhan Corporation
Yuhan Corporation announced on the 13th that it received approval from the Ministry of Food and Drug Safety on the 6th for the phase 1 clinical trial plan of YH34180.
YH34180 is an orally administered small-molecule new drug candidate discovered through Yuhan’s in-house research and development. It is being developed with the goal of reducing inflammatory responses in the kidney and suppressing the occurrence and progression of fibrosis, a process in which tissue becomes hardened, in order to delay renal function decline and related complications.
According to Yuhan, in preclinical studies, kidney function indicators improved in several mouse models administered YH34180, and fibrosis and damage of renal tissue were reduced. An additional improvement effect was also confirmed when it was administered in combination with already approved chronic kidney disease treatments.
This phase 1 clinical trial is the first administration of YH34180 to humans. It will evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics in healthy adult males. The trial will also assess the safety and pharmacokinetic profile when administered in combination with existing standard treatments.
Current treatments for chronic kidney disease include SGLT2 inhibitors, renin-angiotensin system blockers, and mineralocorticoid receptor antagonists. However, even with existing therapies, some patients continue to experience albuminuria, a condition in which albumin, a type of protein, is excreted in the urine, or face gradual deterioration of kidney function.
Yuhan explained that YH34180 has the potential to become a new treatment option by acting on inflammation and fibrosis that are not adequately controlled by existing therapies.
Kim Yeol-hong, Chief R&D Officer at Yuhan Corporation, said, “To overcome the limitations of existing chronic kidney disease treatments, we identified this candidate through our own research and development, and after several years of preclinical development, it has now entered the clinical stage,” adding, “We expect it to alleviate kidney damage through anti-inflammatory and anti-fibrotic effects and plan to begin recruiting trial participants in the near future.”
ⓒ dongA.com. All rights reserved. Reproduction, redistribution, or use for AI training prohibited.
Popular News